<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>glioblastoma therapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/glioblastoma-therapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 18 Nov 2025 00:23:06 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>glioblastoma therapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>SUCLG2 Knockdown Halts Glioblastoma via LMNA, H4K16la</title>
		<link>https://bioengineer.org/suclg2-knockdown-halts-glioblastoma-via-lmna-h4k16la/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 18 Nov 2025 00:22:58 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[glioblastoma therapy]]></category>
		<category><![CDATA[H4K16la lactylation]]></category>
		<category><![CDATA[LMNA acetylation]]></category>
		<category><![CDATA[metabolic-epigenetic crosstalk]]></category>
		<category><![CDATA[SUCLG2 knockdown]]></category>
		<guid isPermaLink="false">https://bioengineer.org/suclg2-knockdown-halts-glioblastoma-via-lmna-h4k16la/</guid>

					<description><![CDATA[In a groundbreaking study that promises to reshape our understanding of glioblastoma biology and therapeutic targeting, researchers have uncovered a novel molecular axis involving SUCLG2, LMNA acetylation, and H4K16la lactylation that fundamentally governs tumor cell proliferation and survival. Published in Cell Death Discovery in late 2025, this research identifies SUCLG2 as a pivotal metabolic enzyme [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">298034</post-id>	</item>
	</channel>
</rss>
